Description
Tackling HIV continues to be a major public health challenge, mainly because the persistence of viral reservoirs means that people living with HIV need to take lifelong antiretroviral treatment. But some individuals, known as “post-treatment controllers,” are able to maintain an undetectable viral load even after stopping treatment. In a study funded by ANRS Emerging Infectious Diseases (ANRS MIE), scientists from the Institut Pasteur, Inserm and the Paris Public Hospital Network (AP-HP) identified specific immunogenetic characteristics in a group of these individuals. The research provides novel information about the immune mechanisms associated with HIV control in the absence of antiretroviral treatment and offers new prospects for the development of immunotherapies aimed at achieving remission or a cure for HIV infection. The research was published in Med on April 28, 2025.
Keywords: HIV, remission, Post-treatment controllers, PTC, ANRS VISCONTI study, NK cells
